Does X(a) mark the spot? An indirect mixed treatment comparison of Xa inhibitors compared to warfarin for patients with atrial fibrillation

Petrou Panagiotis

首页> 外文期刊>Health policy and technology. >Does X(a) mark the spot? An indirect mixed treatment comparison of Xa inhibitors compared to warfarin for patients with atrial fibrillation

【24h】

Does X(a) mark the spot? An indirect mixed treatment comparison of Xa inhibitors compared to warfarin for patients with atrial fibrillation

机译：x（a）标志着现场吗？ XA抑制剂与风心上颤动患者的间接混合治疗比较与华法林相比

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

The study sets out to compare the safety and efficacy of oral Non-vitamin K antagonists and warfarin in patients with atrial fibrillation.

机译：该研究表明，比较口腔非维生素K拮抗剂和华法林在心房颤动患者中的安全性和疗效。

著录项

来源
《Health policy and technology.》 |2019年第3期|共9页
作者
Petrou Panagiotis;
展开▼
作者单位

Univ Nicosia Sch Sci &

Engn Pharm Sch Pharmacoepidemiol Pharmacovigilance Nicosia Cyprus;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词
Atrial fibrillation; Apixaban; Dabigatran; Edoxaban; Rivaroxaban; Stroke prevention;

机译：心房颤动;Apixaban;Dabigatran;埃希伐扎恩;Rivaroxaban;卒中预防;

相似文献

外文文献
中文文献
专利

1. Does X(a) mark the spot? An indirect mixed treatment comparison of Xa inhibitors compared to warfarin for patients with atrial fibrillation [J] . Petrou Panagiotis Health policy and technology. . 2019,第3期

机译：x（a）标志着现场吗？ XA抑制剂与风心上颤动患者的间接混合治疗比较与华法林相比
2. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2) [J] . Lip G. Y. H., Halperin J. L., Petersen P., Journal of thrombosis and haemostasis: JTH . 2015,第8期

机译：II期，双盲，随机，平行分组的剂量对照研究，研究了darexaban与华法林相比在非瓣膜性心房颤动患者中的安全性和耐受性：房颤研究中口服Xa抑制剂预防卒中2 （OPAL-2）
3. Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) (130, pg 138, 2014) [J] . Halperin Jonathan L., Hankey Graeme J., Wojdyla Daniel M., Circulation: An Official Journal of the American Heart Association . 2018,第25期

机译：Rivaroxaban的疗效和安全性与罗西沙巴少年患者的老年患者患者，口服，直接因子XA抑制与维生素K拮抗作用，用于预防心房颤动（Rocket AF）（130，Pg 138,2014）
4. Group-Based Trajectory Analysis for Long-Term Use of Warfarin Therapy in Atrial Fibrillation Patients [C] . Shijing Guo, Xiang Li, Xin Du, MEDINFO . 2017

机译：基于组的术语轨迹分析，用于高级患者的华法林治疗
5. Cost effectiveness of warfarin in anticoagulant clinic after introduction of dabigatran for stroke prevention in atrial fibrillation patients in the United States [D] . Alhazami, Mai S. 2015

机译：在美国引入达比加群后预防心房颤动患者中风后华法林在抗凝临床中的成本效益
6. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2 randomized dose-ranging study (Explore-Xa) [O] . Stuart J. Connolly, John Eikelboom, Paul Dorian, -1

机译：心房纤颤患者中贝曲沙班与华法林的比较：2期随机剂量范围研究的结果（Explore-Xa）
7. A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial [O] . Lip, G. Y. H., Halperin, J. L., Petersen, P., 2017

机译：一项二期，双盲，随机，平行组，剂量发现研究的darexaban与华法林治疗非瓣膜性心房颤动：口服因子Xa抑制剂预防心房卒中

Does X(a) mark the spot? An indirect mixed treatment comparison of Xa inhibitors compared to warfarin for patients with atrial fibrillation

摘要

著录项

相似文献

相关主题

期刊订阅